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Introduction
XP occurs at higher frequency in Tunisia (1:10,000) than in Japan (1:22,000) (Hirai et al. 2006 ) and the United States (1 per million) (Kleijer et al. 2008) . XP-V cells are unable to synthesize intact daughter DNA strands on UV-irradiated templates resulting from an inability to carry out translesion synthesis (Lehmann et al. 1975; Masutani et al. 1999 ). Approximately 20% of XP patients belong to XP-V complementation group (Gratchev et al. 2003) . In Tunisia, XP is classified into three clinical forms: severe, intermediate with or without neurological abnormalities, and moderate (Zghal et al. 2006) . Previous molecular investigation showed homogeneity of mutational spectrum in XPA and XPC genes (Ben Rekaya et al. 2009; Messaoud et al. 2010a,b) . The moderate clinical form of XP is characterized by mild dermatological manifestations, no neurological abnormalities and late onset of skin cancers. The median age of onset is 4 years. Mild skin symptoms and late onset of skin tumours have been already described in XP-V (Tanioka et al. 2007 ), XP-F (Matsumura et al. 1998) and XP-E patients (Rapić-Otrin et al. 2003) . Post-UV cell survival in the presence or absence of caffeine (Itoh et al. 2000) , unscheduled DNA synthesis (UDS) and detection of polymerase eta employing Western blot (Tanioka et al. 2007 ) cannot define exactly the molecular defects are in the polymerase eta. These laboratory assays are used to find out the UV sensitivities of the patients' cells and the DNA repair status of their cells as * For correspondence. E-mail: sonia.abdelhak@pasteur.rns.tn. well as reduced levels or absence of expression of the protein predicts the defects in the polymerase eta. These parameters are very helpful in characterizing the XP patients' cells. The nucleotide sequencing confirms the defects in the XP genes. In the present study, we report the genetic and molecular analyses of POLH gene in a Tunisian patient with mild clinical phenotype suspected to be XP-V.
Materials and methods
The patient is a 75-year-old man who was hospitalized for an ulcerative tumour of the nose. He was born to consanguineous healthy parents and he originated from northwestern Tunisia. Family history revealed an XP affected brother and a paternal cousin who developed skin cancers after 55 years of age. The patient is a farmer by profession. He has no photophobia or ocular lesion. Although was often exposed to sunlight and had never used sunscreen, he did not sunburn easily. He developed two types of cancer separately: a pigmented basal cell carcinoma (BCC) of the left cheek at the age of 71; and a squamous cell carcinoma (SCC) of the labial commissural at the age of 72 (figure 1). Both were treated by surgery. On examination, the patient showed a poïkiloderma facial appearance with an ulcerative tumour on the left wing of the nose. Histological examination of skin biopsy showed a SCC. No ocular or neurological abnormalities were found. The patient had also hearing impairment and tooth decay. The hearing impairment is late onset according to the interview. No further audiometric test was possible. After obtaining patient's informed consent, genomic DNA was extracted from whole peripheral blood by salting out method. Linkage to POLH gene was performed using two informative microsatellite markers spanning a 0.4 Mb interval near to POLH locus (cen-D6S1582, D6S271, (POLH) -tel) (figure 1). Mutations were screened by direct sequencing of exons 10 and 11 of POLH gene.
Results and discussion
The patient developed his first skin cancer at the age of 71 years. This age is over the average age of onset of skin cancer in XP-V patients, estimated at 45 years (Johnson et al. 1999; Masutani et al. 1999; Itoh et al. 2000; Broughton et al. 2002; Tanioka et al. 2007; Inui et al. 2008; Masaki et al. 2008) and it is even higher than the average age of skin cancers in the general Tunisian population (55 years) (Mseddi et al. 2007) . Hearing abnormalities were not previously described in XP-V patients; this particular association observed in the reported case may be due to his old age (presbycusis). Genetic study showed that the patient had a homozygous haplotype (151-168) for markers D6S271 and D6S1582 suggesting linkage to the POLH gene (figure 1). We first screened exon 10 where a previous mutation in a Tunisian XP-V patient was described (Broughton et al. 2002) but no mutation was identified. Considering similar genetic background with the Algerian population, we screened exon 11 in which a mutation has been reported in an Algerian patient (Broughton et al. 2002) . Sequencing of this exon revealed a novel deletion of four bases in homozygous state c.1568_1571delGTCA
(figure 1). This small deletion likely leads to a truncated protein; p.S523KfsX16, containing an intact polymerase activity domain located in the first 511 amino acids (Masutani et al. 1999 ) but lacking the terminal nuclear localization signal (C-NLS) situated between amino acids 682-698 and the PCNA (proliferating cell nuclear antigen) binding site located between amino acids 707 and 708 (Yang and Woodgate 2007) . This suggests that the mutation found in our patient does not reduce the polymerase activity explaining his mild phenotype. Many mutations in the POLH gene have been described in Chinese, American, European and Japanese XP-V patients. Most of them lead to truncated proteins (Masutani et al. 1999; Tanioka et al. 2007; Itoh et al. 2000; Johnson et al. 1999; Broughton et al. 2002; Inui et al. 2008; Masaki et al. 2008) . Only 10% of reported mutations are located in exon 11 although it corresponds to 42% of the coding region (table 1) . This low number of mutations observed in this exon may be due to the under diagnosis of moderate clinical forms (Gratchev et al. 2003) . No correlation between clinical features and the different POLH mutations has been found among previous XP-V reported cases (Tanioka et al. 2007; Inui et al. 2008) . Generally, assessment of phenotype-genotype correlation in patients with XP is complicated because the clinical features are correlated with the degree of exposure to sunlight which is related among others to patient's age. We have previously described a complete phenotype-genotype correlation among Tunisian XP-A and XP-C patients (Ben Rekaya et al. 2009; Messaoud et al. 2010a,b) . To investigate a possible phenotype-genotype correlation we reviewed all XP-V patients reported in the literature who had a mutation in Table 1 . Clinical features of reported XP-V patients with mutations in exon 11 of POLH gene. exon 11 (table 1) (Itoh et al. 2000; Broughton et al. 2002; Tanioka et al. 2007; Inui et al. 2008; Masaki et al. 2008) . Nine patients had mutation at homozygous state in exon 11, while the other five were heterozygous with one mutation in exon 11 and the second located elsewhere. Among the nine homozygous patients three (XPV14KO, XPV11KO and XPV34KE) developed their first skin cancer after the age of 71 years and one 61-years-old patient (XPV17KO) did not have any cancer. In contrast, among the five compound heterozygous patients, two (XPV8HM and XPV16KO) developed their first skin cancer at the age of 25 and 35 years respectively; one patient XP1AB (51 years old) developed more than 50 skin cancers and the patient XP139DC had BCC at 19 years. For Ops4, who has two mis-sense mutations in the catalytic domain, as he was 8 years old, he is too young to develop skin cancers (table 1). It seems that patients having a mutation at the homozygous state in exon 11 shared a milder phenotype than patients being compound heterozygous (only one allele mutated in exon 11 and the other affecting upstream of exon 11 thus likely affecting the catalytic domain) (figure 2). A previous study revealed that healthy individuals who are heterozygous for POLH mutation showed reduced levels of recovery of replicative DNA synthesis in the presence of caffeine after UV irradiation (Itoh et al. 2000) . A phenotype-genotype correlation could be established in XP-V patients when a distinction is made between homozygous and compound heterozygous patients. Based on all cases published analysis, we hypothesize that mutations outside the catalytic domain of pol eta is always associated with a very mild phenotype regardless of the type of mutation. Generally many factors might be related to the development of skin cancers such as the localization of the mutation, accumulation of sun exposure, lifestyle of a patient and other genetic determinants like protective polymorphisms (Masaki et al. 2008) .
Taking into account the geographic and demographic features in Tunisia, i.e a sunny weather exposing to UV radiation and the high rate of endogamy that contributes to an increase in genetic diseases, it would be of great interest to perform mutation screening of POLH gene in patients showing photosensitivity in an effort to prevent skin cancer. 
